摘要
新型的抗TNF-α制剂阿达木单抗(Adalimumab)是一种经皮下注射的重组人源性Ig G1型抗TNF-α抗体。已应用于临床的生物制剂有英夫利昔(Infliximab)、阿达木单抗(Adalimumab)、赛妥珠单抗(Certolizumab)、那他珠单抗(Natalizumab)等,其中以英夫利昔应用时间最长。生物制剂对中重度溃疡性结肠炎(UC)及克罗恩病(CD)患者可诱导和维持缓解,减少或停止糖皮质激素的应用,促进黏膜愈合,提高患者生活质量。阿达木单抗对英夫利昔单抗不耐受或失去应答的患者有较好的疗效,并能促进瘘管型CD患者的瘘管闭合。但随着生物制剂在临床应用越来越广泛及应用时间的延长,生物制剂在治疗炎症性肠病中的安全性倍受关注,本文对此作一概述。
Adalimumab is a subcutaneously administered, fully humanized anti-TNF-ct monoclonal IgG1 antibody. The biological agents that have applied in clinic include Infliximab, Adalimumab, Certolizumab, Natalizumab and so on. Among these, Infliximab has been used for the longest time. The biological agents are effective in inducing and maintaining clinical response and remission in patients with moderate to severe IBD, which can reduce or stop potential steroid usage, promote mucosal healing and improve the quality of life in these patients. Adalimumab also has been shown to be beneficial to patients who lose response or are intolerant to Infiximab and to promote the closure of the fistula orifice. However, with the biological agents having been used more and more widely and durably, the safety of the bio- logical agents in the treatment of IBD has attracted more and more concern.
出处
《胃肠病学和肝病学杂志》
CAS
2016年第2期226-230,共5页
Chinese Journal of Gastroenterology and Hepatology
关键词
炎症性肠病
生物制剂
不良反应
Inflammatory bowel disease
Biological agents
Adverse reactions
